Precision Cancer Drugs Use DNA Logic to Target Tumors

Got story updates? Submit your updates here. ›

Researchers at the University of Geneva have developed a new drug-delivery system that uses synthetic DNA, affibodies, and aptamers to create an 'on/off' switch that triggers a therapeutic payload only when a precise pair of cancer cell markers appear in combination. This approach aims to increase the precision and selectivity of cancer treatments by abandoning the traditional 'one-cue' paradigm and instead using an 'AND' logic gate that requires two separate biomarkers to be present before activating the drug.

Why it matters

The old guard of targeted cancer therapies often relies on a single marker or broad tumor features, leading to off-target effects and collateral damage. The Geneva approach uses a more sophisticated multiplex signature, reducing the likelihood of side effects and potentially lowering the required drug dose. This shift toward context-aware, programmable medicines could make cancer treatment more selective and effective by reading the tumor's microenvironment as a larger system rather than chasing a single beacon.

The details

The core of the system is a DNA hairpin that remains inert until two biomarker-specific binders meet on the same cell. Only then does a hybridization chain reaction unfold, cascading into a payload activation. This allows the drug to be delivered selectively to cancer cells while leaving healthy cells relatively unharmed. The platform's modularity also allows researchers to swap markers, payloads, or add immune-system recruitment components in a plug-and-play fashion, enabling personalized treatment strategies tailored to each patient's tumor profile.

• The University of Geneva team published their findings in April 2026.

What’s next

The researchers will need to address challenges around DNA stability in plasma and the fragility of certain aptamers before the technology can be translated to clinical trials. Engineering solutions like mirrored DNA or chemical stabilizers will be essential, but are considered solvable problems rather than showstoppers.